Search research articles
Contact Us
Filters
Showing results (201-210 of 224) with videos related to
Page
of 23
Sort By:
Journal for Immunotherapy of Cancer
|
January 8, 2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Janis M Taube, Joel C Sunshine, Michael Angelo, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
Cancer Discovery
|
February 22, 2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M Fischer, Ali Jalali, David A Kircher, et al.
The Journal of Experimental Medicine
|
August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 224) with videos related to
Sort By:
Page
of 23
Journal for Immunotherapy of Cancer
|
January 8, 2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Janis M Taube, Joel C Sunshine, Michael Angelo, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
Cancer Discovery
|
February 22, 2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M Fischer, Ali Jalali, David A Kircher, et al.
The Journal of Experimental Medicine
|
August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Page
of 23